Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation
Launched by JAHN FERENC SOUTH PEST TEACHING HOSPITAL · Dec 2, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to deliver medications directly into the bladder without using a catheter, which is a tube that is usually inserted into the body. This method, called catheter-free intravesical instillation, is being tested for patients with conditions like interstitial cystitis (bladder pain syndrome), recurrent urinary tract infections, bladder cancer, and for those who have had bladder irritation after chemotherapy or radiation. The goal of the study is to see if this new method is more comfortable and has fewer complications than traditional catheter-based treatments, while still being effective.
To participate in the trial, you need to be between 18 and 80 years old and have one of the specified bladder conditions. It's important that you have not had a urinary tract infection in the last two weeks and can provide consent to join the study. If you qualify, you can expect to receive treatment through this new method and share your experience, which will help researchers understand its impact on comfort and effectiveness.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female patients aged between 18 and 80 years.
- * Patients for whom the treating physician has determined that intravesical instillation is necessary due to one of the following conditions:
- • Interstitial cystitis/bladder pain syndrome (IC/BPS).
- • Recurrent urinary tract infections (UTIs).
- • Non-muscle invasive bladder cancer.
- • Post-radiation cystitis.
- • Post-chemotherapy cystitis.
- • Negative urine culture within the last two weeks.
- • Patients who provide verbal and written informed consent to participate in the study.
- Exclusion Criteria:
- • Urinary tract infection within the past month or currently active infection.
- • Diagnosed bleeding disorders or recurrent macroscopic hematuria.
- • Post-void residual urine volume greater than 100 ml.
- • Mental condition that prevents reliable cooperation.
About Jahn Ferenc South Pest Teaching Hospital
Jahn Ferenc South Pest Teaching Hospital is a leading healthcare institution dedicated to providing high-quality medical services and advancing clinical research. As a prominent teaching hospital, it combines patient care with education and research, fostering an environment of innovation and excellence in medical practices. The hospital is committed to conducting rigorous clinical trials that contribute to the development of new therapies and improve patient outcomes. With a focus on collaboration among multidisciplinary teams, Jahn Ferenc South Pest Teaching Hospital aims to enhance medical knowledge and promote evidence-based practices in the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Budapest, , Hungary
Budapest, , Hungary
Patients applied
Trial Officials
Peter Tenke, Professor of Urology
Study Chair
South Pest Teaching Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported